Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound that serves as an E3 ligase ligand-linker. It features a cereblon ligand based on Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology.
Thalidomide-5-propargyne-NH2 hydrochloride is a cereblon ligand derived from Thalidomide that is utilized in the recruitment of CRBN protein. It can be linked to the protein ligand through a linker to produce PROTACs, which are compounds used for protein degradation.
Thalidomide-5-CH2-NH2 (hydrochloride) is a derivative of Thalidomide that serves as a cereblon ligand, specifically utilized for the recruitment of CRBN protein. This compound, Thalidomide-5-CH2-NH2 (hydrochloride), can be connected to a protein ligand through a linker, resulting in the formation of PROTACs.
Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.
Thalidomide-NH-PEG4-Ms is a conjugate that consists of a cereblon ligand based on Thalidomide and a linker molecule, which serves as a ligand-linker moiety for E3 ligase. This conjugate is specifically designed as a degrader for PROTAC BCL-XL, known as XZ739.
Thalidomide-PEG4-NH2 hydrochloride is a compound synthesized as an E3 ligase ligand-linker conjugate. It encompasses the cereblon ligand derived from Thalidomide and a linker utilized specifically in PROTAC technology.
Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate. This compound combines the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly employed in PROTAC technology. [1]
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.
Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].
Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker designed for use in antibody-drug conjugates (ADCs). This compound can be coupled to a protein ligand via a linker to create PROTAC iRucaparib-AP6, an extremely selective degrader of PARP1[1].
Thalidomide-O-amido-C8-NH2 hydrochloride is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker. It can be utilized in the synthesis of PROTACs[1].
Thalidomide-O-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a linker. It is commonly employed in the synthesis of PROTACs[1].
Thalidomide-O-C6-COOH is a synthetic conjugate comprising an E3 ligase ligand-linker, which combines the Thalidomide derived cereblon ligand with a PROTAC technology linker.
Thalidomide-O-C3-acid is a chemically derived conjugate that combines a cereblon ligand based on Thalidomide and a linker commonly employed in PROTAC technology. This synthesized E3 ligase ligand-linker conjugate serves to facilitate targeted protein degradation.
Thalidomide-O-C8-NH2 is a chemically synthesized conjugate that combines a cereblon ligand derived from Thalidomide with a linker utilized in PROTAC technology. It functions as an E3 ligase ligand-linker conjugate.
Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC5 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Pomalidomide - linker 4 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate compound that combines a Thalidomide-based cereblon ligand with a linker commonly used in PROTAC technology. It acts as an E3 ligase ligand-linker conjugate, enabling targeted protein degradation.
Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate. It incorporates a cereblon ligand based on Thalidomide and a linker component commonly utilized in PROTAC technology.
Thalidomide-NH-C8-NH2 hydrochloride is a synthetic compound, which functions as an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, along with a linker commonly used in PROTAC technology.